Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can exercise save your muscles while on Weight-Loss drugs? new trial aims to find out

NCT ID NCT07609160

Disease control Sponsor: Acibadem University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a 24-week home-based resistance exercise program, when added to the weight-loss drug tirzepatide, helps overweight and obese adults maintain muscle mass and strength. About 108 people starting tirzepatide will be randomly assigned to either exercise plus the drug or the drug alone. Researchers will measure changes in thigh muscle thickness and quality using ultrasound.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide
What this could lead to
If successful, this could show that combining exercise with tirzepatide helps overweight people lose weight while keeping muscle strength and quality.
What could go wrong
This is a small, early-stage trial (108 people) that hasn't started yet. The exercise is home-based, so results may vary, and tirzepatide can cause side effects like nausea or digestive issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 108 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * initiation of tirzepatide-based pharmacological treatment as prescribed by an endocrinology and metabolism specialist, * body mass index (BMI) ≥27 kg/m² and the presence of a comorbidity condition or BMI≥30 kg/m² * age between 18 and 65 years Exclusion Criteria: * diagnosis of type 1 or type 2 diabetes mellitus * presence of cerebrovascular, hematological, pulmonary, rheumatological, or neurological disorders * current participation in a structured diet or exercise program * use of weight-loss medications within the past 12 months * history of upper or lower extremity surgery or injury within the past 6 months * any contraindication to resistance exercise as determined by the treating physician.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Motor Activity Obesity obesity disorder Overweight Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight (without type 2 diabetes) with weight-related comorbidities Sarcopenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.